Patients often ask who makes the best medical cannabis in Israel. There is no official answer. The Health Ministry's Medical Cannabis Unit (Yakar) licenses producers and inspects them, but it does not grade or rank them, and any list online that calls itself "top-rated" reflects someone's opinion. What is available is a set of public records that let you check the things that matter: whether a company is licensed, who actually grew and packed a product, what that batch tested at, whether the producer's products have been pulled from shelves, and whether the company is financially stable enough to keep supplying you. This guide explains where to find each of those records.
This guide is general information about the supply chain, not medical advice. It does not claim that any producer's products are more effective than another's. Do not change a prescribed product without speaking to your prescribing physician.
1. Check the licence register
Yakar's register of licence holders is published as an open dataset (data.gov.il, "Holders of a cannabis business licence", Hebrew). The version dated 14 September 2026 has 305 entries across roughly 250 distinct company names. Our tally by licence type:
| Licence type | Entries |
|---|---|
| Cultivation sites (flower) | 26 |
| Propagation sites (seedlings) | 31 |
| Manufacturing plants | 8 |
| Trading houses (wholesale/import) | 24 |
| Testing laboratories | 19 |
| Secure transport | 9 |
| Certification bodies (quality and security) | 2 |
| Destruction sites | 3 |
| Other licensed operators | 113 |
| Licence or quality certificate frozen or cancelled | 70 |
The last row is the one to look at. The register flags 70 entries whose licence or IMC quality certificate has been frozen or cancelled. The flagged entries include companies once familiar to patients, among them two growing companies named Cann Better and several CannAssure companies. The register does not say whether a given entry was frozen or cancelled, when, or why, so a flag is a prompt to check further, not a verdict. Several companies also hold separate entries for different activities, so a frozen growing licence does not necessarily mean the whole group has stopped operating. For the wider picture of who farms cannabis in Israel, see who grows medical cannabis in Israel.
2. Find out who actually made it
The brand on a jar is not always the grower. Israeli packs name the licence holders that grew, processed and packed the product, and those names can be checked against the register. Marketing companies still sometimes sell flower grown by an unnamed partner farm. When the Ministry withdrew one Tikun Olam indica product in May 2025, Hebrew-language Cannabis Magazine noted that the product had been packed at the David and Goliath plant and marketed by a company that did not disclose which farm grew it (Cannabis Magazine, 14 May 2025, Hebrew). A large share of the flower sold in Israel is also imported, mainly from Canada, which means the "producer" on the shelf may be a trading house rather than a farm. How that supply works is covered in Israel's cannabis imports.
3. Read the batch certificate
This is the most useful check, and it takes seconds. Under the Ministry's Procedure 152, every legal product must show its measured THC, CBD and CBN content for that production batch and a QR code linking to the batch certificate. The manufacturer is required to publish that certificate on its website (Ministry of Health, Procedure 152, Hebrew). A producer that keeps its certificates easy to find, complete and consistent from batch to batch is showing you something a ranking cannot. A missing certificate, or one that does not match the pack, is worth raising with the pharmacist. What each field means is explained in Israel's IMC-GMP quality standards.
4. Look for withdrawals and rejected batches
We could not find a central, searchable public archive of cannabis product withdrawals in Israel. Withdrawals have become known through Ministry notices to pharmacies and through press reports, so a news search on the producer's name is worth doing.
The clearest recent case came in May 2025. Within about two weeks the Ministry barred three products from sale. The Ministry told Cannabis Magazine that routine Yakar inspections had sampled several products for laboratory testing, and that two of them, Tikun Olam's NEO indica and a product called M212, were withdrawn over pesticide residues above the permitted threshold. A third, Mini D&C, was first reported as withdrawn for the same reason but was later corrected to a non-conformity with its product file. All three had been packed at the same plant (Cannabis Magazine, 28 May 2025, Hebrew). When the first order was issued, the same outlet described it as the first time in years that the Ministry had ordered a medical cannabis product off the shelves (Cannabis Magazine, 14 May 2025).
Some problems are caught before anything reaches a pharmacy. In a lawsuit reported in September 2026, the licensed farm Cann4Life says routine testing before packing found the insecticide acetamiprid in three flower batches worth ₪868,557, which were then rejected. It blames a crop product that was sold as pesticide-free. The manufacturer denies the claims and the case is undecided. The filing does not suggest that any of the rejected product reached patients (Cannabis Magazine, 24 September 2026, Hebrew). Israeli product exported abroad has faced the same scrutiny. In 2021 the UK's medicines regulator ran a precautionary recall of two batches made by BOL Pharma after patients reported suspected mould (Cannabis Health News).
One withdrawal does not make a producer unsafe, and a clean record may partly reflect how rarely products are sampled. Patients have long complained that routine sampling of products already on sale was infrequent (Cannabis Magazine). What a withdrawal record does show is how a company responds when something goes wrong.
5. Check the company's financial health
A producer that fails can take your usual product off the market with it, and the domestic industry is under real strain. Israel's largest finishing plant, Bazelet, entered insolvency proceedings with some NIS 153 million of debt, and the David and Goliath plant faced a liquidation petition from its own employees. Both are covered in Bazelet: how Israel's largest cannabis plant went insolvent. The best-known brand of the early years lost its farms and closed its last plant in 2025, as told in what happened to Tikun Olam. Listed companies publish their results. The profiles of InterCure (Canndoc) and IM Cannabis show what those filings reveal.
6. Compare what you actually pay
The same product can cost a third more at one pharmacy than at another. Price is a legitimate factor, but compare like with like: the same product and category, bought at the pharmacies near you. The pharmacy side, including a September 2026 price survey of 68 pharmacies, is covered in where to buy medical cannabis in Israel.
What a ranking cannot tell you
A potency figure is not a quality score. Products are sold in standard THC/CBD categories, and a T22/C4 flower, for example, is supposed to fall in a fixed THC band whichever company made it. The whole point of the IMC-GMP system is that a product in a given category should behave the same way from batch to batch and from producer to producer. We are not aware of evidence that one Israeli producer's products are more effective than another's at the same category, and patient reviews cannot establish that either. The checks above are about trust and continuity: whether the product is legal, traceable, tested, still on sale next month, and fairly priced.
Profiles of the larger licensed operators are in our directory of Israeli cannabis companies. For the wider industry picture, return to the Companies hub.
Compiled and reviewed by Tamar Levin, Editor. Sources are linked inline. This guide is informational and is not medical or legal advice; consult a licensed physician about your own treatment.
More on this topic: Companies.